Migraine

>

Latest News

Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents / image credit ©Lightspring/shutterstock.com
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents

February 27th 2025

While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.

Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial

February 25th 2025

FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose / image credit: ©New Africa/AdobeStock
FDA Greenlights Symbravo for Acute Treatment of Migraine: Daily Dose

February 6th 2025

New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments  image credit  ©Parata/stock.adobe.com
New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments

February 5th 2025

Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD / image credit Geisel School of Medicine, Dartmouth
Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD

February 4th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.